Keyphrases
Novel Mechanism
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
HF with Preserved Ejection Fraction
80%
Ejection Fraction
40%
Heart Failure
30%
Mid-range Ejection Fraction
30%
European Society of Cardiology Guidelines
20%
Drug Therapy
10%
Health Systems
10%
Obesity
10%
Type 2 Diabetes Mellitus (T2DM)
10%
Drug Efficacy
10%
Epidemiological Study
10%
Quality of Life Improvement
10%
Myocardial Infarction
10%
Mortality Rate
10%
Renal Failure
10%
Pharmacological Approaches
10%
Diagnosis Treatment
10%
Atrial Fibrillation
10%
High Morbidity
10%
High Mortality
10%
Arterial Hypertension
10%
Diastolic Dysfunction
10%
Systolic Dysfunction
10%
Clinical Phenotype
10%
Left Ventricular Hypertrophy
10%
Long-term Clinical Outcome
10%
Heart Failure Patients
10%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
10%
Morbidity Rate
10%
Heterogeneous Pathophysiology
10%
Cardiomyocyte Death
10%
Major Outbreak
10%
Reduced Ejection Fraction
10%
Drug-induced Myopathy
10%
Yacoub
10%
Treatment Provision
10%
Holistic Treatment
10%
Natriuretic Peptides
10%
Viral Myocarditis
10%
Non-cardiac Comorbidity
10%
Structural Heart Disease
10%
Myocardial Remodeling
10%
Left Atrial Enlargement
10%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Heart Failure with Reduced Ejection Fraction
100%
Pharmacotherapy
16%
Pathophysiology
16%
Hypertension
16%
Heart Infarction
16%
Kidney Failure
16%
Atrial Fibrillation
16%
Brain Natriuretic Peptide
16%
Heart Left Ventricle Hypertrophy
16%
Diastolic Dysfunction
16%
Heart Disease
16%
Mortality Rate
16%
Morbidity
16%
Heart Atrium Enlargement
16%
Systolic Dysfunction
16%
Heart Failure with Preserved Ejection Fraction
16%
Natriuretic Factor
16%
Virus Myocarditis
16%
Non Insulin Dependent Diabetes Mellitus
16%
Comorbidity
16%
Myocardial Disease
16%
Medicine and Dentistry
Ejection Fraction
100%
Congestive Heart Failure
100%
Heart Failure with Reduced Ejection Fraction
35%
Cardiology
11%
Quality of Life
5%
Drug Therapy
5%
Mortality Rate
5%
Hypertension
5%
Maturity Onset Diabetes of the Young
5%
Myocardial Infarction
5%
Pathophysiology
5%
Renal Failure
5%
Heart Disease
5%
Cardiac Muscle Cell
5%
Atrial Fibrillation
5%
Diastolic Dysfunction
5%
Systolic Dysfunction
5%
Left Ventricular Hypertrophy
5%
Morbidity
5%
Heart Failure with Preserved Ejection Fraction
5%
Left Atrial Enlargement
5%
Virus Myocarditis
5%
Natriuretic Factor
5%
Brain Natriuretic Peptide
5%
Comorbidity
5%
Myocardial Disease
5%